(Circulation. 2000;101:1812.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Department of Genetics and Howard Hughes Medical Institute, Harvard Medical School (J.S., H.L., S.S., D.F., C.M., J.G.S., C.E.S.), the Department of Pulmonary Medicine, Childrens Hospital (H.L.), the Massachusetts Eye and Ear Infirmary (H.S., C.H., R.E.), and the Cardiovascular Division and Howard Hughes Medical Institute, Brigham and Womens Hospital, (C.E.S.), Boston, Mass; the University of Heidelberg, Department of Medicine III, Heidelberg, Germany (E.G.); the Section of Heart Failure and Cardiac Transplantation, Henry Ford Hospital, Detroit, Mich (E.F.P.); and the University of Lübeck, Department of Medicine II, Lübeck, Germany (H.K.).
Correspondence to Christine E. Seidman, MD, Dept of Genetics/Alpert Room 533, Harvard Medical School, 200 Longwood Avenue, Boston MA 02115. E-mail cseidman{at}rascal.med.harvard.edu
| Abstract |
|---|
|
|
|---|
Methods and ResultsClinical evaluations of 2 kindreds demonstrated autosomal-dominant transmission and age-related penetrance of both SNHL and DCM in the absence of other disorders. Moderate-to-severe hearing loss was evident by late adolescence, whereas ventricular dysfunction produced progressive congestive heart failure after the fourth decade. DNA samples from the larger kindred (29 individuals) were used to perform a genome-wide linkage study. Polymorphic loci on chromosome 6q23 to 24 were coinherited with the disease (maximum logarithm of odds score, 4.88 at locus D6S2411). The disease locus must lie within a 2.8 cM interval between loci D6S975 and D6S292, a location that overlaps an SNHL disease locus (DFNA10). However, DFNA10 does not cause cardiomyopathy. The epicardin gene, which encodes a transcription factor expressed in the myocardium and cochlea, was assessed as a candidate gene by nucleotide sequence analysis; no mutations were identified.
ConclusionsA syndrome of juvenile-onset SNHL and adult-onset DCM is caused by a mutation at 6q23 to 24 (locus designated CMD1J). Recognition of this cardioauditory disorder allows for the identification of young adults at risk for serious heart disease, thereby enabling early intervention. Definition of the molecular cause of this syndrome may provide new information about important cell physiology common to both the ear and heart.
Key Words: cardiomyopathy hearing loss, sensorineural genetics
| Introduction |
|---|
|
|
|---|
60% of early-onset hearing loss. More
than 40 different nonsyndromic deafness loci have been reported.
Cochlear hair cell and/or neuronal malfunction of the inner ear cause
sensorineural hearing loss (SNHL).1 2 3 4 Dilated cardiomyopathy (DCM), a disorder characterized by ventricular dilation and contractile dysfunction, is a leading cause of heart failure, with a prevalence of 36.5 per 100 000 individuals.5 Several studies indicate that 25% to 30% of DCM is familial,6 7 8 but the definition of the genomic location of the disease loci and the identification of disease genes has been hindered both by the significant mortality and the late age of onset of this disease. Nevertheless, 7 DCM loci (CMD1A-G) have been defined in this genetically heterogeneous disease.9 10 11 12 13 14 15 Although the disease genes at these loci have not been identified, 2 disease genes for DCM, actin and desmin, have been identified by candidate gene approaches.16 17
Many human syndromes exhibit heart and ear abnormalities in association with other organ disease.18 Alstrom syndrome, which was recently mapped to chromosome 2p12 to 13,19 causes DCM and hearing impairment in the setting of cone-rod ocular dystrophy, obesity, and noninsulin-dependent diabetes.20 Rosenberg syndrome causes X-linked cardiomyopathy and SNHL with hyperuricemia and ataxia.18 Mutations in mitochondria tRNAs perturb cardiac function and hearing,21 22 23 but they typically have associated encephalomyelopathy, skeletal myopathies, and/or metabolic abnormalities; these defects are further distinguished by matrilineal inheritance.
The finding of cardioauditory disease in the absence of other disease is rare. The classic example is Jervell and Lange-Nielsen syndrome, a disorder characterized by congenital deafness and cardiac arrhythmias (long-QT syndrome); notably, in this disease, cardiac structure is normal. Genetic studies of Jervell and Lange-Nielsen syndrome have demonstrated that recessive mutations in the KVLQT1 gene on chromosome 11p15.5 or the ISK gene on chromosome 21q22.1 to 22.224 25 cause this disorder.
We report a new heritable cardioauditory syndrome characterized by postlingual SNHL with DCM and demonstrate that the causal mutation maps to chromosome 6q23 to 24 (locus designation CMD1J). This unique phenotype provides advantages for the identification of candidate genes and establishes an early marker for identifying individuals at risk for significant cardiac disease.
| Methods |
|---|
|
|
|---|
Hearing was assessed by air and bone conduction and word recognition, as determined using 50-item Central Institute for the Deaf Wordlist 22 on compact disk.28 The level for word-recognition testing was set to a region of maximum performance as predicted by the Articulation Index, and it was never <55 dB of hearing loss.29 Hearing deficits were classified as absent, mild, moderate, moderate/severe, severe, or profound on the basis of the degree of hearing loss at <27, 27 to 40, 41 to 55, 56 to 70, 71 to 90, and >90 dB of hearing level, respectively.1 Disease status of deceased individuals was based on medical records.
Genetic Studies
Linkage studies were performed using DNA extracted from whole
blood or Epstein Barr virustransformed lymphocytes, as previously
described.30 Linkage analyses used short tandem
repeat markers spaced
10 cM apart (Weber 8.0 Panel, Research
Genetics). Polymerase chain reaction amplification was performed in a
10-µL reaction containing 20 ng of genomic DNA,
fluorescence-labeled primers, and standard reagents for
standard reaction times. Reaction products were pooled and mixed
with size standards according to the manufacturers recommendations
(Applied Biosystems Inc). Product sizes were determined on a 6%
denaturing polyacrylamide gel using an ABI
377, with Genescan and
Genotyper software (Perkin-Elmer). Alleles
were determined without knowledge of clinical status.
Two-point logarithm of odds scores were calculated using MLINK (version 5.1), assuming a penetrance of 95% and a phenocopy rate of 0.001. Allele frequencies were determined from genotypes of unrelated individuals.
The order of loci used in haplotype constructions was based on the physical mapping data derived from the Whitehead Physical Mapping Project31 or determined using physical mapping of a yeast artificial chromosome contig. Candidate genes and expressed sequence tags were defined within the disease interval on the basis of yeast artificial chromosome content mapping.
Mutational Analysis of Epicardin
A 10-kilobase EcoRI fragment of PAC 524A10 (Roswell Park Cancer
Institute) containing the epicardin gene was identified by
hybridization with an epicardin cDNA probe (amplified using
primers exon 1a-F and exon 2-R, below). This PAC maps to the human 6q23
to 24 region.32 A 10 kb fragment was subcloned into
pBluescript. Positive clones selected by hybridization to
this cDNA probe were expanded for DNA extraction (Qiagen) and sequenced
using ABI 377 Big Dye sequence technology. Exon-intron
boundaries were deduced from comparison with the cDNA sequence (Genbank
accession number AF04741933 ). Primers corresponding to
intron sequences external to splice signals were constructed and used
to amplify and sequence exons encoding epicardin, as
follows:
Exon 1a-F: CATTCGGGAGGCCTCTTGGTTTCA
Exon 1a-R: CCGCTCAGGGGGCTCTTCTTG
Exon 1b-F: CGGCGGCCTGGGCAAGAG
Exon 1b-R: GCGCCCTCACCCCCACTCC
Exon 2-F: CCTTTCATCTCAGGCCCCGAGTCC
Exon 2-R: GTTCTCGCGGGGTGGGACAG
Sequences of samples from affected and unaffected individuals were compared using ABI 377 and DNA-Star SeqMan software.
| Results |
|---|
|
|
|---|
|
|
|
Three of four individuals with DCM in family MDB (Figure 3
) also had SNHL. Family history and
medical records indicated hearing deficits occurred by early
adulthood and preceded cardiac symptoms. Audiological evaluations were
not performed on individual I-2, and her hearing phenotype was
assigned unknown status. Progressive congestive
cardiomyopathy characterized the DCM found in
family MDB and caused the death of 2 individuals (II-1 and II-4); in
one instance, death was sudden. Individual II-6 has been listed for
cardiac transplantation. Significant coronary disease was
excluded in some individuals by angiography (II-4, II-6) or autopsy
(II-1).
|
The gross pathological examination of the heart specimen obtained from individual III-2 from family MCE revealed an enlarged, globular heart weighing 620 g. Histological examination demonstrated hypertrophic myocytes with enlarged hyperchromatic nuclei and increased interstitial fibrous connective tissue. Comparable findings of idiopathic DCM were described in the pathology reports of explanted hearts from individuals III-3 and III-5.
Pedigree analyses of families MCE and MDB were
consistent with autosomal-dominant inheritance and age-related
penetrance of SNHL (onset in second decade) with DCM (onset in fourth
decade). Karyotypes of affected individuals from each family were
normal (data not shown). Genome-wide linkage analyses were
performed to map the disease locus in family MCE. The analysis
of 280 polymorphic loci excluded >80% of the genome before
linkage was identified with markers at 6q23 to 24 (Table 2
). When the 4 young individuals (IV-1,
IV-3, IV-5 and IV-6; <40 years) with SNHL but no clinical signs of
cardiomyopathy were assigned an "unknown"
status for linkage analyses, a maximum logarithm of odds
score of 3.98 (at
=0) was achieved at locus D6S2411.
However, if either SNHL or DCM was used as the diagnostic
criterion for disease, the maximum logarithm of odds was 4.88 (at
=0), indicating a likelihood of 75 000:1 that the disease gene is
encoded in this region.
|
To refine the disease interval, genotypes were analyzed
at nearby loci (Figure 4
), and a disease
haplotype was deduced (Figure 1
). Recombination events were
identified in 2 individuals: genotype was discordant with
affection status in II-3 at D6S975 and in III-2 at
D6S292, thereby defining a disease interval that spans 2.8
cM.
|
Analyses of chromosome 6q23 to 24 polymorphic loci in family MDB neither proved nor excluded linkage due to the limited size of this pedigree. The disease alleles found in affected individuals of family MCE were not present in individual II-6 of family MDB, which excluded a shared disease haplotype.
Candidate Gene Analysis
The disease interval contains 7 known genesepicardin,
c-Myb, SGK, EYA4, TLP, Btf, and eRFSand several other
genes encoding expressed sequence tags. The mesenchymal basic
helix-loop-helix transcription factor epicardin (also known
as capsulin and Pod-1),34 35 has been mapped
to a region of mouse chromosome 10 that is syntenic to human chromosome
6q23 to 24.36 Epicardin expression has been
demonstrated during murine cardiac development and in
interstitial cells of the adult mouse
myocardium.37 We detected
epicardin transcripts in human cardiac and cochlear cDNA
libraries (data not shown) and amplified epicardin sequences
from the overlapping yeast artificial chromosome clones 917C6 and
916H10 and P1 artificial chromosomes clone 524A10, which are contained
in the disease interval. To determine if a deletion or rearrangement of
the epicardin gene caused SNHL and DCM in family MCE,
Southern blot analyses (after EcoR1, HindIII, and BamHI
restriction enzyme digests) were performed; they were identical in DNA
derived from 3 affected and 3 unaffected individuals (data not shown).
DNA sequence analyses of epicardin exons and
flanking splice signals, introns, and untranslated regions were
performed (data not shown). A 4-bp deletion was found in a
CT-rich element in the 5' untranslated region, but the deletion
represented a common polymorphism that did not
segregate with disease. Because some affected individuals were
heterozygous for this polymorphism, the disease-causing mutation
cannot be a large deletion of the entire epicardin gene. We
did not detect any epicardin gene defects that could cause
SNHL and DCM in affected members of family MCE.
| Discussion |
|---|
|
|
|---|
Two disease genes, DFNA1038 and CMD1F,9 map in or near the CMD1J locus. DFNA10 is responsible for deafness in affected members of several large families. Although heritable heart disease was not recognized as a feature of deafness caused by DFNA10, we cannot exclude the possibility that a different defect in the same gene or a defect in a contiguous gene could account for the cardiac defects in MCE family members. Although CMD1F mutations do cause DCM, we do not think that these loci are allelic for several reasons. (1) The disease intervals do not overlap. (2) Hearing loss has not been observed in individuals with CMD1F mutations. (3) The skeletal myopathy seen with the CMD1F mutation was not observed in our patients.
SNHL with DCM in families MCE and MDB could reflect a mutation of a single protein with important biological function in both the ear and heart, as in Jervell and Lange-Nielsen syndrome (long-QT syndrome with deafness). Mutations in K+ channel components encoded by KVLQT1 or ISK genes cause this recessive disorder. In the heart, these defects delay myocellular repolarization,39 whereas in the ear, mutations prevent the secretion of potassium into endolymph, changing the ionic environment necessary for normal hair cell function.40 Although we hypothesized that mutations in epicardin, a basic helix-loop-helix transcription factor encoded within the disease interval and expressed in cardioauditory tissues, might cause SNHL with DCM, no defects were identified. Continued analyses of genes that are coexpressed in these tissues may help explain the pleiotropic phenotypes found in families MCE and MDB.
These data extend the heterogeneity of human mutations that cause DCM. Although the incidence of hereditary cardioauditory disease is likely low, the clinical recognition and dissection of the molecular cause of this disorder has value for identifying molecules whose function is critical for cardiac biology. The late onset of disease and premature death are substantial hurdles that limit the power of molecular genetic approaches to study DCM. Indeed, genome-wide linkage analyses of the cardiac phenotype in family MCE might have been difficult. However, the recognition of hearing deficits that preceded heart disease, thus allowing SNHL to indicate affection status, significantly increased the power of genetic studies. Coexistence of disease in the myocardium and inner ear will also be of use in ongoing efforts to identify the disease gene. More immediately, recognition of the association between hearing deficits and cardiomyopathy has clinical importance. The identification of SNHL in an individual can prompt close monitoring and early intervention, practices that may ultimately reduce the high morbidity and mortality of DCM in these families.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received August 23, 1999; revision received October 27, 1999; accepted November 15, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
L. Zhang, A. Hu, H. Yuan, L. Cui, G. Miao, X. Yang, L. Wang, J. Liu, X. Liu, S. Wang, et al. A Missense Mutation in the CHRM2 Gene Is Associated With Familial Dilated Cardiomyopathy Circ. Res., June 6, 2008; 102(11): 1426 - 1432. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Burkett and R. E. Hershberger Clinical and genetic issues in familial dilated cardiomyopathy J. Am. Coll. Cardiol., April 5, 2005; 45(7): 969 - 981. [Abstract] [Full Text] [PDF] |
||||
![]() |
S A Mohiddin, Z M Ahmed, A J Griffith, D Tripodi, T B Friedman, L Fananapazir, and R J Morell Novel association of hypertrophic cardiomyopathy, sensorineural deafness, and a mutation in unconventional myosin VI (MYO6) J. Med. Genet., April 1, 2004; 41(4): 309 - 314. [Full Text] [PDF] |
||||
![]() |
P. A. Doevendans Genetic Polymorphisms and Cardiac Failure Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 23 - 29. [PDF] |
||||
![]() |
D. Fatkin and R. M. Graham Molecular Mechanisms of Inherited Cardiomyopathies Physiol Rev, October 1, 2002; 82(4): 945 - 980. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Crispell, E. L. Hanson, K. Coates, W. Toy, and R. E. Hershberger Periodic rescreening is indicated for family members at risk of developing familial dilated cardiomyopathy J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1503 - 1507. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. F. Benson and K. Chada Molecular Characterization of the Mouse In(10)17Rk Inversion and Identification of a Novel Muscle-Specific Gene at the Proximal Breakpoint Genetics, January 1, 2002; 160(1): 279 - 287. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wayne, N. G. Robertson, F. DeClau, N. Chen, K. Verhoeven, S. Prasad, L. Tranebjarg, C. C. Morton, A. F. Ryan, G. Van Camp, et al. Mutations in the transcriptional activator EYA4 cause late-onset deafness at the DFNA10 locus Hum. Mol. Genet., February 1, 2001; 10(3): 195 - 200. [Abstract] [Full Text] [PDF] |
||||
![]() |
M KOMAJDA Genetics of dilated cardiomyopathy: a molecular maze? Heart, November 1, 2000; 84(5): 463 - 464. [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |